<DOC>
	<DOC>NCT02774278</DOC>
	<brief_summary>This study will assess potentially predictive markers of efficacy in participants with NSCLC receiving oral erlotinib (Tarceva) therapy. The anticipated time on study treatment is until disease progression, unacceptable toxicity or death.</brief_summary>
	<brief_title>A Study of Erlotinib (Tarceva) in Participants With Non-Small Cell Lung Cancer (NSCLC)</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Advanced NSCLC Tumor accessible for biopsy by bronchoscopy Disease progression following course of standard chemotherapy, or participants unwilling/unable to undergo chemotherapy Unstable systemic disease Any other malignancies in the last 5 years Brain metastases Previous treatment with therapy acting on the epidermal growth factor receptor (EGFR) axis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>